The trial, sponsored by the National Institute of Allergy and Infectious Diseases, included more than 1,000 hospitalized patients and discovered that those receiving remdesivir recovered faster than those who got a placebo: in 11 days, versus 15 days. Remdesivir is authorized only for seriously ill patients and just briefly; formal approval should come later. Talking about this issue with another scientist at a conference, Dr. Denison discovered that Gilead Sciences had lots of drugs that may do the trick. But none of this might show that a drug was handy to patients. Even a modest result from the drug in hospitalized clients was a surprise, said Dr. Arnold Monto, an epidemiologist at the University of Michigan.
The trial, sponsored by the National Institute of Allergy and Infectious Diseases, included more than 1,000 hospitalized clients and found that those receiving remdesivir recovered faster than those who got a placebo: in 11 days, versus 15 days. But none of this might demonstrate that a drug was useful to patients. Even a modest impact from the drug in hospitalized patients was a surprise, said Dr. Arnold Monto, an epidemiologist at the University of Michigan.
from WordPress https://ift.tt/2Sq4tOu
Keine Kommentare:
Kommentar veröffentlichen